nutriband shares were up 14 to 273 on friday after the company said it expanded its existing credit line facility to 5 million to fund the continued development and regulatory submission process for its patented lead product aversa fentanyl an abusedeterrent fentanyl transdermal system the stock hit its 52week low of 192 on june 26 and is down 34 over the past 12 months aversa fentanyl is the flagship product of the pharmaceutical companys aversa platform the company said the proprietary technology can be incorporated into transdermal patches that help improve the safety profile and prevent abuse and exposure of drugs such as fentanyl the company said it is targeting a us food and drug administration submission for aversa fentanyl in the first half of 2024 aversa fentanyl was recently estimated to have the potential to reach peak annual us sales of 80 million to 200 million the aversa technology is covered by a broad intellectual property portfolio in 45 countries with patents granted in the us europe uk japan korea russia canada mexico and australia